{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T15:14:09Z","timestamp":1793459649287,"version":"4.5.0"},"reference-count":107,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2016,10,1]],"date-time":"2016-10-01T00:00:00Z","timestamp":1475280000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["journal-of-hepatology.eu","clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Hepatology"],"published-print":{"date-parts":[[2016,10]]},"DOI":"10.1016\/j.jhep.2016.07.039","type":"journal-article","created":{"date-parts":[[2016,9,16]],"date-time":"2016-09-16T05:04:27Z","timestamp":1474002267000},"page":"S95-S108","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":155,"special_numbering":"S","title":["Reversion of disease manifestations after HCV eradication"],"prefix":"10.1016","volume":"65","author":[{"given":"Adriaan J.","family":"van der Meer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marina","family":"Berenguer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jhep.2016.07.039_b0005","unstructured":"World Health Organization Fact sheet N\u00b0164, accessed June 2013 at http:\/\/www.who.int\/mediacentre\/factsheets\/fs164\/en\/."},{"key":"10.1016\/j.jhep.2016.07.039_b0010","doi-asserted-by":"crossref","first-page":"2608","DOI":"10.1056\/NEJMoa1512612","article-title":"Sofosbuvir and velpatasvir for HCV genotype 2 and 3 infection","volume":"373","author":"Foster","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jhep.2016.07.039_b0015","doi-asserted-by":"crossref","first-page":"S188","DOI":"10.1016\/S0168-8278(16)00128-8","article-title":"Retreatment of patients who failed DAA-combination therapies: real-world experience from a large hepatitis C resistance database","volume":"64","author":"Vermehren","year":"2016","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2016.07.039_b0020","doi-asserted-by":"crossref","first-page":"S160","DOI":"10.1016\/S0168-8278(16)01668-8","article-title":"High efficacy of ABT-493 and ABT-530 in HCV genotype 1 infected patients who have failed direct-acting antiviral-containing regimens: the Megallan-I study","volume":"64","author":"Poordad","year":"2016","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2016.07.039_b0025","doi-asserted-by":"crossref","first-page":"S139","DOI":"10.1016\/S0168-8278(16)01645-7","article-title":"High efficacy of sofosbuvir\/velpatasvir plus GS-9857 for 12 weeks in treatment-experienced genotype 1\u20136 HCV-infected patients, including those previously treated with direct antivirals","volume":"64","author":"Lawitz","year":"2016","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2016.07.039_b0030","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1016\/j.jhep.2012.06.030","article-title":"Fatigue before, during and after antiviral therapy of chronic hepatitis C: results from the Virahep-C study","volume":"57","author":"Sarkar","year":"2012","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2016.07.039_b0035","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1016\/j.jhep.2008.07.025","article-title":"Deterioration of health-related quality of life and fatigue in patients with chronic hepatitis C: Association with demographic factors, inflammatory activity, and degree of fibrosis","volume":"49","author":"Teuber","year":"2008","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2016.07.039_b0040","doi-asserted-by":"crossref","first-page":"2204","DOI":"10.1002\/1529-0131(199910)42:10<2204::AID-ANR24>3.0.CO;2-D","article-title":"Extrahepatic manifestations of chronic hepatitis C. MULTIVIRC Group. Multidepartment Virus C","volume":"42","author":"Cacoub","year":"1999","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.jhep.2016.07.039_b0045","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1176\/appi.ajp.157.6.867","article-title":"Neuropsychiatric symptoms associated with hepatitis C and interferon alpha: A review","volume":"157","author":"Dieperink","year":"2000","journal-title":"Am J Psychiatry"},{"key":"10.1016\/j.jhep.2016.07.039_b0050","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1093\/infdis\/jis385","article-title":"Chronic hepatitis C virus infection increases mortality from hepatic and extrahepatic diseases: a community-based long-term prospective study","volume":"206","author":"Lee","year":"2012","journal-title":"J Infect Dis"},{"key":"10.1016\/j.jhep.2016.07.039_b0055","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1002\/hep.20659","article-title":"Impact of hepatitis C on health related quality of life: a systematic review and quantitative assessment","volume":"41","author":"Spiegel","year":"2005","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2016.07.039_b0060","doi-asserted-by":"crossref","first-page":"S110","DOI":"10.1016\/j.jhep.2016.07.005","article-title":"Hepatitis C infection: a multi-faceted systemic disease with clinical, patient reported and economic consequences","volume":"65","author":"Younossi","year":"2016","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2016.07.039_b0065","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1016\/j.jhep.2007.11.022","article-title":"Effect of sustained virological response to treatment on the incidence of abnormal glucose values in chronic hepatitis C","volume":"48","author":"Romero-Gomez","year":"2008","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2016.07.039_b0070","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1002\/hep.22703","article-title":"Sustained virological response reduces incidence of onset of type 2 diabetes in chronic hepatitis C","volume":"49","author":"Arase","year":"2009","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2016.07.039_b0075","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1002\/hep.27623","article-title":"Long-term effect of HCV eradication in patients with mixed cryoglobulinemia: A prospective, controlled, open-label, cohort study","volume":"61","author":"Gragnani","year":"2015","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2016.07.039_b0080","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.1016\/j.amjmed.2007.06.022","article-title":"Viral elimination reduces incidence of malignant lymphoma in patients with hepatitis C","volume":"120","author":"Kawamura","year":"2007","journal-title":"Am J Med"},{"key":"10.1016\/j.jhep.2016.07.039_b0085","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1136\/gutjnl-2014-308163","article-title":"Association between antiviral treatment and extrahepatic outcomes in patients with hepatitis C virus infection","volume":"64","author":"Hsu","year":"2015","journal-title":"Gut"},{"key":"10.1016\/j.jhep.2016.07.039_b0090","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1002\/hep.27766","article-title":"Towards a more complete understanding of the association between a hepatitis C sustained viral response and cause-specific outcomes","volume":"62","author":"Innes","year":"2015","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2016.07.039_b0095","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1111\/j.1365-2893.2012.01591.x","article-title":"Hepatitis C virus and the brain","volume":"19","author":"Fletcher","year":"2012","journal-title":"J Viral Hepat"},{"key":"10.1016\/j.jhep.2016.07.039_b0100","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1111\/liv.13071","article-title":"Viral eradication reduces all-cause mortality in patients with chronic hepatitis C virus infection: a propensity score analysis","volume":"36","author":"Tada","year":"2016","journal-title":"Liver Int"},{"key":"10.1016\/j.jhep.2016.07.039_b0105","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1093\/cid\/cis500","article-title":"Sustained virological response to interferon plus ribavirin reduces non-liver-related mortality in patients coinfected with HIV and Hepatitis C virus","volume":"55","author":"Berenguer","year":"2012","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jhep.2016.07.039_b0110","doi-asserted-by":"crossref","first-page":"2247","DOI":"10.1074\/jbc.275.4.2247","article-title":"Molecular regulation of hepatic fibrosis, an integrated cellular response to tissue injury","volume":"275","author":"Friedman","year":"2000","journal-title":"J Biol Chem"},{"key":"10.1016\/j.jhep.2016.07.039_b0115","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1016\/0168-8278(95)80226-6","article-title":"Histological grading and staging of chronic hepatitis","volume":"22","author":"Ishak","year":"1995","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2016.07.039_b0120","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1002\/hep.510240201","article-title":"An algorithm for the grading of activity in chronic hepatitis C. The METAVIR Cooperative Study Group","volume":"24","author":"Bedossa","year":"1996","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2016.07.039_b0125","first-page":"H460","article-title":"Hepatic microvascular changes associated with development of liver fibrosis and cirrhosis","volume":"258","author":"Sherman","year":"1990","journal-title":"Am J Physiol"},{"key":"10.1016\/j.jhep.2016.07.039_b0130","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1016\/j.jhep.2004.03.007","article-title":"Cirrhosis reversal: a duel between dogma and myth","volume":"40","author":"Desmet","year":"2004","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2016.07.039_b0135","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.1053\/jhep.2002.32524","article-title":"Hypoxia-induced VEGF and collagen I expressions are associated with angiogenesis and fibrogenesis in experimental cirrhosis","volume":"35","author":"Corpechot","year":"2002","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2016.07.039_b0140","doi-asserted-by":"crossref","first-page":"2886","DOI":"10.1111\/j.1572-0241.2002.07057.x","article-title":"Effect of hepatitis B and C virus infections on the natural history of compensated cirrhosis: a cohort study of 297 patients","volume":"97","author":"Fattovich","year":"2002","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.jhep.2016.07.039_b0145","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1053\/gast.1997.v112.pm9024300","article-title":"Morbidity and mortality in compensated cirrhosis type C: a retrospective follow-up study of 384 patients","volume":"112","author":"Fattovich","year":"1997","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2016.07.039_b0150","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1016\/j.cgh.2009.11.018","article-title":"A sustained viral response is associated with reduced liver-related morbidity and mortality in patients with hepatitis C virus","volume":"8","author":"Singal","year":"2010","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.jhep.2016.07.039_b0155","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1002\/hep.22375","article-title":"Estimation of stage-specific fibrosis progression rates in chronic hepatitis C virus infection: a meta-analysis and meta-regression","volume":"48","author":"Thein","year":"2008","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2016.07.039_b0160","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1001\/jamainternmed.2014.6502","article-title":"Liver fibrosis progression in hepatitis C virus infection after seroconversion","volume":"175","author":"Butt","year":"2015","journal-title":"JAMA Intern Med"},{"key":"10.1016\/j.jhep.2016.07.039_b0165","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1002\/hep.26644","article-title":"Evaluation of liver disease progression in the German hepatitis C virus (1b)-contaminated anti-D cohort at 35 years after infection","volume":"59","author":"Wiese","year":"2014","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2016.07.039_b0170","doi-asserted-by":"crossref","first-page":"S623","DOI":"10.1016\/S0168-8278(16)01157-0","article-title":"Insight into hepatitis C virus infection; a cohort study of women infected with contaminated anti-D immunoglobulin in Ireland between 1977 and 1979","volume":"64","author":"Garvey","year":"2016","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2016.07.039_b0175","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1053\/j.gastro.2009.09.067","article-title":"Aging of hepatitis C virus (HCV)-infected persons in the United States: a multiple cohort model of HCV prevalence and disease progression","volume":"138","author":"Davis","year":"2010","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2016.07.039_b0180","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1016\/j.jhep.2004.12.031","article-title":"Estimating the impact of hepatitis C virus therapy on future liver-related morbidity, mortality and costs related to chronic hepatitis C","volume":"42","author":"Buti","year":"2005","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2016.07.039_b0185","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1016\/j.jhep.2011.09.024","article-title":"Clinical evidence for the regression of liver fibrosis","volume":"56","author":"Ellis","year":"2012","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2016.07.039_b0190","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1053\/gast.2002.33023","article-title":"Impact of pegylated interferon alfa-2b and ribavirin on liver fibrosis in patients with chronic hepatitis C","volume":"122","author":"Poynard","year":"2002","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2016.07.039_b0195","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1002\/hep.22694","article-title":"Clinical, virologic, histologic, and biochemical outcomes after successful HCV therapy: a 5-year follow-up of 150 patients","volume":"49","author":"George","year":"2009","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2016.07.039_b0200","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1002\/hep.25606","article-title":"A morphometric and immunohistochemical study to assess the benefit of a sustained virological response in hepatitis C virus patients with cirrhosis","volume":"56","author":"D\u2019Ambrosio","year":"2012","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2016.07.039_b0205","doi-asserted-by":"crossref","first-page":"517","DOI":"10.7326\/0003-4819-132-7-200004040-00002","article-title":"Histologic improvement of fibrosis in patients with hepatitis C who have sustained response to interferon therapy","volume":"132","author":"Shiratori","year":"2000","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jhep.2016.07.039_b0210","doi-asserted-by":"crossref","first-page":"1168","DOI":"10.1111\/jgh.13252","article-title":"Improvement of platelets after SVR among patients with chronic HCV infection and advanced hepatic fibrosis","volume":"31","author":"van der Meer","year":"2016","journal-title":"J Gastroenterol Hepatol"},{"key":"10.1016\/j.jhep.2016.07.039_b0215","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1002\/hep.25606","article-title":"A morphometric and immunohistochemical study to assess the benefit of a sustained virological response in hepatitis C virus patients with cirrhosis","volume":"56","author":"D\u2019Ambrosio","year":"2012","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2016.07.039_b0220","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1016\/S0016-5085(03)00973-9","article-title":"Reversal of cirrhosis: evidence-based medicine?","volume":"125","author":"Desmet","year":"2003","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2016.07.039_b0225","doi-asserted-by":"crossref","first-page":"399","DOI":"10.7326\/0003-4819-149-6-200809160-00006","article-title":"Brief communication: the relationship of regression of cirrhosis to outcome in chronic hepatitis C","volume":"149","author":"Mallet","year":"2008","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jhep.2016.07.039_b0230","doi-asserted-by":"crossref","first-page":"3473","DOI":"10.1007\/s10620-015-3773-y","article-title":"Fibrosis regression explains differences in outcome in HIV-\/HCV-coinfected patients with cirrhosis after sustained virological response","volume":"60","author":"Casado","year":"2015","journal-title":"Dig Dis Sci"},{"key":"10.1016\/j.jhep.2016.07.039_b0235","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1016\/j.cgh.2007.02.022","article-title":"Effect of sustained viral response on hepatic venous pressure gradient in hepatitis C-related cirrhosis","volume":"5","author":"Roberts","year":"2007","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.jhep.2016.07.039_b0240","doi-asserted-by":"crossref","first-page":"2269","DOI":"10.1111\/j.1572-0241.2006.00743.x","article-title":"Antiviral therapy decreases hepatic venous pressure gradient in patients with chronic hepatitis C and advanced fibrosis","volume":"101","author":"Rincon","year":"2006","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.jhep.2016.07.039_b0245","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1016\/j.jhep.2007.01.003","article-title":"Hepatology may have problems with putative surrogate outcome measures","volume":"46","author":"Gluud","year":"2007","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2016.07.039_b0250","doi-asserted-by":"crossref","first-page":"S221","DOI":"10.1016\/S0168-8278(16)00195-1","article-title":"HCV eradication results in reduction of hepatic venous pressure gradient 48 weeks after end of treatment; final results of the study of sofosbuvir plus ribavirin in patients with cirrhosis and portal hypertension","volume":"64","author":"Afdhal","year":"2016","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2016.07.039_b0255","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1016\/j.jhep.2016.05.027","article-title":"Sustained virologic response to interferon-free therapies ameliorates HCV-induced portal hypertension","volume":"65","author":"Mandorfer","year":"2016","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2016.07.039_b0260","doi-asserted-by":"crossref","first-page":"677","DOI":"10.7326\/0003-4819-147-10-200711200-00003","article-title":"Sustained virologic response and clinical outcomes in patients with chronic hepatitis C and advanced fibrosis","volume":"147","author":"Veldt","year":"2007","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jhep.2016.07.039_b0265","doi-asserted-by":"crossref","first-page":"2584","DOI":"10.1001\/jama.2012.144878","article-title":"Association between sustained virological response and all-cause mortality among patients with chronic hepatitis C and advanced hepatic fibrosis","volume":"308","author":"Van der Meer","year":"2012","journal-title":"JAMA"},{"key":"10.1016\/j.jhep.2016.07.039_b0270","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1002\/hep.23744","article-title":"Outcome of sustained virological responders with histologically advanced chronic hepatitis C","volume":"52","author":"Morgan","year":"2010","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2016.07.039_b0275","doi-asserted-by":"crossref","first-page":"65","DOI":"10.3851\/IMP2827","article-title":"Long-term survival and liver-related events after pegylated interferon\/ribavirin therapy in HIV-infected patients with chronic hepatitis C","volume":"20","author":"Labarga","year":"2015","journal-title":"Antivir Ther"},{"key":"10.1016\/j.jhep.2016.07.039_b0280","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1016\/j.jhep.2009.12.028","article-title":"Impact of peginterferon and ribavirin therapy on hepatocellular carcinoma: incidence and survival in hepatitis C patients with advanced fibrosis","volume":"52","author":"Cardoso","year":"2010","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2016.07.039_b0285","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1002\/hep.21492","article-title":"Sustained virological response to interferon-alpha is associated with improved outcome in HCV-related cirrhosis: a retrospective study","volume":"45","author":"Bruno","year":"2007","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2016.07.039_b0290","doi-asserted-by":"crossref","first-page":"329","DOI":"10.7326\/0003-4819-158-5-201303050-00005","article-title":"Eradication of hepatitis C virus infection and the development of hepatocellular carcinoma: a meta-analysis of observational studies","volume":"158","author":"Morgan","year":"2013","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jhep.2016.07.039_b0295","first-page":"280A","article-title":"The risk for hepatocellular carcinoma among patients with chronic HCV infection and advanced hepatic fibrosis following sustained virological response","volume":"58","author":"Van der Meer","year":"2013","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2016.07.039_b0300","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1016\/j.cgh.2011.03.004","article-title":"A sustained virologic response reduces risk of all-cause mortality in patients with hepatitis C","volume":"9","author":"Backus","year":"2011","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.jhep.2016.07.039_b0305","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/j.jhep.2013.07.043","article-title":"Is there sufficient evidence to recommend antiviral therapy in hepatitis C?","volume":"60","author":"Van der Meer","year":"2014","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2016.07.039_b0310","first-page":"CD003617","article-title":"Interferon for interferon nonresponding and relapsing patients with chronic hepatitis C","volume":"1","author":"Koretz","year":"2013","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.jhep.2016.07.039_b0315","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1093\/cid\/cit234","article-title":"A risk for hepatocellular carcinoma persists long-term after sustained virologic response in patients with hepatitis C-associated liver cirrhosis","volume":"57","author":"Aleman","year":"2013","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jhep.2016.07.039_b0320","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1093\/cid\/civ396","article-title":"Long-term treatment outcomes of patients infected with hepatitis C virus: A systematic review and meta-analysis of the survival benefit of achieving a sustained virological response","volume":"61","author":"Simmons","year":"2015","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jhep.2016.07.039_b0325","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1111\/jvh.12185","article-title":"The number needed to treat to prevent mortality and cirrhosis-related complications among patients with cirrhosis and HCV genotype 1 infection","volume":"21","author":"Van der Meer","year":"2014","journal-title":"J Viral Hepat"},{"key":"10.1016\/j.jhep.2016.07.039_b0330","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1016\/j.jhep.2016.01.034","article-title":"Survival of patients with HCV cirrhosis and sustained virologic response is similar to the general population","volume":"64","author":"Bruno","year":"2016","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2016.07.039_b0335","doi-asserted-by":"crossref","first-page":"1927","DOI":"10.1001\/jama.2014.12627","article-title":"Life expectancy in patients with chronic HCV infection and cirrhosis compared with a general population","volume":"312","author":"Van der Meer","year":"2014","journal-title":"JAMA"},{"key":"10.1016\/j.jhep.2016.07.039_b0340","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1111\/j.1478-3231.2006.01260.x","article-title":"Sustained viral response prolonged survival of patients with C-viral hepatocellular carcinoma","volume":"26","author":"Akamatsu","year":"2006","journal-title":"Liver Int"},{"key":"10.1016\/j.jhep.2016.07.039_b0345","doi-asserted-by":"crossref","first-page":"299","DOI":"10.7326\/0003-4819-138-4-200302180-00008","article-title":"Interferon therapy after tumor ablation improves prognosis in patients with hepatocellular carcinoma associated with hepatitis C virus","volume":"138","author":"Shiratori","year":"2003","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jhep.2016.07.039_b0350","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1016\/j.jhep.2016.04.008","article-title":"Unexpected early tumor recurrence in patients with hepatitis C virus -related hepatocellular carcinoma undergoing interferon-free therapy: a note of caution","volume":"65","author":"Reig","year":"2016","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2016.07.039_b0355","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1016\/j.jhep.2016.05.045","article-title":"Lack of evidence of an effect of Direct Acting Antivirals on the recurrence of hepatocellular carcinoma: The ANRS collaborative study group on hepatocellular carcinoma (ANRS CO22 HEPATHER, CO12 CIRVIR and CO23 CUPILT cohorts)","volume":"65","author":"Pol","year":"2016","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2016.07.039_b0360","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1053\/j.gastro.2010.12.032","article-title":"Increasing prevalence of HCC and cirrhosis in patients with chronic hepatitis C virus infection","volume":"140","author":"Kanwal","year":"2011","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2016.07.039_b0365","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1016\/S0168-8278(03)00310-6","article-title":"Antiviral therapy of patients with decompensated cirrhosis to prevent recurrence of hepatitis C after liver transplantation","volume":"39","author":"Forns","year":"2003","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2016.07.039_b0370","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1016\/j.jhep.2006.08.020","article-title":"Peginterferon alfa-2b and ribavirin in patients with hepatitis C virus and decompensated cirrhosis: a controlled study","volume":"46","author":"Iacobellis","year":"2007","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2016.07.039_b0375","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/j.cgh.2010.10.036","article-title":"Long-term outcome after antiviral therapy of patients with hepatitis C virus infection and decompensated cirrhosis","volume":"9","author":"Iacobellis","year":"2011","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.jhep.2016.07.039_b0380","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.1002\/hep.28446","article-title":"Daclatasvir with sofosbuvir and ribavirin for hepatitis C virus infection with advanced cirrhosis or post-liver transplantation recurrence","volume":"63","author":"Poordad","year":"2016","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2016.07.039_b0385","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1016\/S1473-3099(16)00052-9","article-title":"Ledipasvir and sofosbuvir plus ribavirin in patients with genotype 1 or 4 hepatitis C virus infection and advanced liver disease: a multicentre, open-label, randomised, phase 2 trial","volume":"16","author":"Manns","year":"2016","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.jhep.2016.07.039_b0390","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1053\/j.gastro.2015.05.010","article-title":"Ledipasvir and sofosbuvir plus ribavirin for treatment of HCV infection in patients with advanced liver disease","volume":"149","author":"Charlton","year":"2015","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2016.07.039_b0395","doi-asserted-by":"crossref","first-page":"2618","DOI":"10.1056\/NEJMoa1512614","article-title":"Sofosbuvir and velpatasvir for HCV in patients with decompensated cirrhosis","volume":"373","author":"Curry","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jhep.2016.07.039_b0400","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.1016\/j.jhep.2016.01.029","article-title":"Impact of direct acting antiviral therapy in patients with chronic hepatitis C and decompensated cirrhosis","volume":"64","author":"Foster","year":"2016","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2016.07.039_b0405","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1002\/hep.27937","article-title":"Multicenter experience using simeprevir and sofosbuvir with or without ribavirin to treat hepatitis C genotype 1 in patients with cirrhosis","volume":"62","author":"Aqel","year":"2015","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2016.07.039_b0410","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1016\/j.jhep.2012.02.033","article-title":"Hepatitis B virus-related decompensated liver cirrhosis: benefits of antiviral therapy","volume":"57","author":"Peng","year":"2012","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2016.07.039_b0415","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1053\/jlts.2002.32983","article-title":"Effect of lamivudine treatment on survival of 309 North American patients awaiting liver transplantation for chronic hepatitis B","volume":"8","author":"Fontana","year":"2002","journal-title":"Liver Transpl"},{"key":"10.1016\/j.jhep.2016.07.039_b0420","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1053\/gast.2002.35352","article-title":"Determinants of early mortality in patients with decompensated chronic hepatitis B treated with antiviral therapy","volume":"123","author":"Fontana","year":"2002","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2016.07.039_b0425","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1002\/lt.24051","article-title":"Patient with decompensated hepatitis C virus-related cirrhosis delisted for liver transplantation after successful sofosbuvir-based treatment","volume":"21","author":"Ruiz","year":"2015","journal-title":"Liver Transpl"},{"key":"10.1016\/j.jhep.2016.07.039_b0430","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1016\/j.jhep.2016.05.010","article-title":"Delisting of liver transplant candidates with chronic hepatitis C after viral eradication: A European study","volume":"65","author":"Belli","year":"2016","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2016.07.039_b0435","first-page":"257A","article-title":"Improving liver function and delisting of patients awaiting liver transplantation for HCV cirrhosis: Do we ask too much to DAA?","volume":"62","author":"Coilly","year":"2015","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2016.07.039_b0440","unstructured":"FDA, accessed July 2016 at: http:\/\/www.fda.gov\/Safety\/MedWatch\/SafetyInformation\/SafetyAlertsforHumanMedicalProducts\/ucm468757.htm."},{"key":"10.1016\/j.jhep.2016.07.039_b0445","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1016\/j.jhep.2015.11.034","article-title":"Lactic acidosis in patients with hepatitis C virus cirrhosis and combined ribavirin\/sofosbuvir treatment","volume":"64","author":"Welker","year":"2016","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2016.07.039_b0450","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1016\/j.jhep.2016.01.007","article-title":"Hepatic decompensation during direct-acting antiviral therapy of chronic hepatitis C","volume":"64","author":"Hoofnagle","year":"2016","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2016.07.039_b0455","doi-asserted-by":"crossref","first-page":"1527","DOI":"10.1111\/j.1440-1746.2005.03886.x","article-title":"Timing of lamivudine administration according to Child class in patients with decompensated cirrhosis","volume":"20","author":"Bae","year":"2005","journal-title":"J Gastroenterol Hepatol"},{"key":"10.1016\/j.jhep.2016.07.039_b0460","doi-asserted-by":"crossref","first-page":"S185","DOI":"10.1016\/S0168-8278(16)01699-8","article-title":"Antiviral treatment in patients with advanced HCV cirrhosis using sofosbuvir and ledipasvir\/daclatasvir with or without ribavirin - 6 and 12 month outcomes compared to untreated patients","volume":"64","author":"Cheung","year":"2016","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2016.07.039_b0465","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1111\/ctr.12596","article-title":"A pleasant dilemma to have: to treat the HCV patient on the waiting list or to treat post-liver transplantation?","volume":"29","author":"Barsa","year":"2015","journal-title":"Clin Transplant"},{"key":"10.1016\/j.jhep.2016.07.039_b0470","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1016\/j.jhep.2012.12.014","article-title":"Progression of liver fibrosis in post-transplant hepatitis C: mechanisms, assessment and treatment","volume":"58","author":"Berenguer","year":"2013","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2016.07.039_b0475","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1016\/j.jhep.2008.05.002","article-title":"Systematic review of the treatment of established recurrent hepatitis C with pegylated interferon in combination with ribavirin","volume":"49","author":"Berenguer","year":"2008","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2016.07.039_b0480","doi-asserted-by":"crossref","first-page":"2426","DOI":"10.1111\/j.1600-6143.2008.02362.x","article-title":"Impact of pegylated interferon and ribavirin treatment on graft survival in liver transplant patients with recurrent hepatitis C infection","volume":"8","author":"Veldt","year":"2008","journal-title":"Am J Transplant"},{"key":"10.1016\/j.jhep.2016.07.039_b0485","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1097\/TP.0b013e3181bd783c","article-title":"Antiviral treatment of recurrent hepatitis C after liver transplantation: predictors of response and long-term outcome","volume":"88","author":"Selzner","year":"2009","journal-title":"Transplantation"},{"key":"10.1016\/j.jhep.2016.07.039_b0490","doi-asserted-by":"crossref","first-page":"1766","DOI":"10.1002\/lt.21635","article-title":"Hepatitis C virus therapy in liver transplant recipients: response predictors, effect on fibrosis progression, and importance of the initial stage of fibrosis","volume":"14","author":"Roche","year":"2008","journal-title":"Liver Transpl"},{"key":"10.1016\/j.jhep.2016.07.039_b0495","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1016\/j.jhep.2006.10.017","article-title":"Sustained virological response to antiviral therapy reduces mortality in HCV reinfection after liver transplantation","volume":"46","author":"Picciotto","year":"2007","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2016.07.039_b0500","doi-asserted-by":"crossref","first-page":"1909","DOI":"10.1111\/j.1600-6143.2005.00976.x","article-title":"Benefit of sustained virological response to combination therapy on graft survival of liver transplanted patients with recurrent chronic hepatitis C","volume":"5","author":"Bizollon","year":"2005","journal-title":"Am J Transplant"},{"key":"10.1016\/j.jhep.2016.07.039_b0505","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1111\/j.1600-6143.2007.02126.x","article-title":"Clinical benefits of antiviral therapy in patients with recurrent hepatitis C following liver transplantation","volume":"8","author":"Berenguer","year":"2008","journal-title":"Am J Transplant"},{"key":"10.1016\/j.jhep.2016.07.039_b0510","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1002\/lt.20074","article-title":"Sustained viral response to interferon and ribavirin in liver transplant recipients with recurrent hepatitis C","volume":"10","author":"Abdelmalek","year":"2004","journal-title":"Liver Transpl"},{"key":"10.1016\/j.jhep.2016.07.039_b0515","doi-asserted-by":"crossref","DOI":"10.1136\/bmjgast-2015-000066","article-title":"Tolerability and effectiveness of sofosbuvir and simeprevir in the post-transplant setting: systematic review and meta-analysis","volume":"3","author":"Nguyen","year":"2016","journal-title":"BMJ Open Gastroenterol"},{"key":"10.1016\/j.jhep.2016.07.039_b0520","doi-asserted-by":"crossref","first-page":"1993","DOI":"10.1016\/j.cgh.2015.05.030","article-title":"Efficacy of sofosbuvir and daclatasvir in patients with fibrosing cholestatic hepatitis C after liver transplantation","volume":"13","author":"Leroy","year":"2015","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.jhep.2016.07.039_b0525","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1002\/lt.24416","article-title":"Daclatasvir combined with sofosbuvir or simeprevir in liver transplant recipients with severe recurrent hepatitis C infection","volume":"22","author":"Fontana","year":"2016","journal-title":"Liver Transpl"},{"key":"10.1016\/j.jhep.2016.07.039_b0530","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1016\/j.jhep.2016.05.039","article-title":"Multicentre experience using daclatasvir and sofosbuvir to treat hepatitis C recurrence after liver transplantation \u2013 The CO23 ANRS CUPILT study","volume":"65","author":"Coilly","year":"2016","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2016.07.039_b0535","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.1002\/hep.27681","article-title":"Sofosbuvir compassionate use program for patients with severe recurrent hepatitis C after liver transplantation","volume":"61","author":"Forns","year":"2015","journal-title":"Hepatology"}],"container-title":["Journal of Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168827816304147?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168827816304147?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,8]],"date-time":"2018-09-08T11:29:54Z","timestamp":1536406194000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168827816304147"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,10]]},"references-count":107,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2016,10]]}},"alternative-id":["S0168827816304147"],"URL":"https:\/\/doi.org\/10.1016\/j.jhep.2016.07.039","relation":{},"ISSN":["0168-8278"],"issn-type":[{"value":"0168-8278","type":"print"}],"subject":[],"published":{"date-parts":[[2016,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Reversion of disease manifestations after HCV eradication","name":"articletitle","label":"Article Title"},{"value":"Journal of Hepatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jhep.2016.07.039","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}